Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Temsirolimus in Recurrent Endometrial Carcinoma
NCT00723255Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2008
- Primary completion
- Jul 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, temsirolimus in endometrial carcinoma, sponsored by National Cancer Institute. Started Sep 2008; status: completed.
02
Drugs
bevacizumabtemsirolimus
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00723255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00723255.